Source briefingSeptember 18, 2026Human Rights

Blood test trend versus single threshold abnormality to discriminate cancer from non-cancer in patients with unexpected weight loss: A retrospective cohort study

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.

What the source reports

by Brian D. Nicholson, Clare R. Bankhead, Sufen Zhu, Jason Lee Oke, Cynthia Wright Drakesmith, Rafael Perera, Frederick D. Richard Hobbs, Pradeep S.

Virdee Background Unexpected weight loss (UWL) is a non-specific cancer symptom. Abnormalities in the most recent blood test contribute to cancer referral decisions in primary care. Interpreting historical changes (trends) in blood tests could enhance discrimination for undiagnosed cancer. We aimed to assess the discrimination of blood test trend for undiagnosed cancer and compare this to that of blood…

Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.

Source & verification

Primary source: PLOS Medicine · September 17, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EMA/PE/0000181364

What is established The European Medicines Agency (EMA) has granted a decision regarding a paediatric investigation plan (PIP) for vosoritide as of 8 August…

EMA/PE/0000228795

Evidence Dossier: EMA Paediatric Investigation Plan for Ambrisentan/Tadalafil What is established The European Medicines Agency (EMA) has officially adopted a paediatric investigation plan (PIP)…

EMA/PE/0000261344

Evidence Dossier: EMA Decision on Colchicine Paediatric Investigation Plan (PIP) What is established On 8 August 2025, the European Medicines Agency (EMA) granted a…